BioTuesdays

Category - Feature

Feature

Alpha Cancer to test oncology game changer

By Len Zehr Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug...

March 11, 2014
Feature

Gamida Cell shifts focus to NiCord stem cell product

By Len Zehr Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an...

March 4, 2014
Feature

Advaxis readies cervical cancer pivotal trial

By Len Zehr Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the...

February 25, 2014
Feature

In conversation with Michael Vidne

By Len Zehr As director of business development for closely held NovellusDx, Michael Vidne has an enviable position in one of the hottest areas of health care: personalized medicine. A former consultant in the West...

February 11, 2014
Feature

Venaxis pivotal APPY1 data due in March

By Len Zehr Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a final...

February 4, 2014
Feature

In conversation with Elias Vamvakas

By Len Zehr As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED)...

January 28, 2014
Feature

Encision to launch simplified AEM device

By Len Zehr The new management team at Encision (OTC:ECIA) plans to launch in late spring a simplified version of its Active Electrode Monitoring (AEM) technology, known as the EndoShield Burn Protection System, to...

January 21, 2014
Feature

Alcobra’s ADHD program moving to pediatrics

By Len Zehr With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric...

January 14, 2014
Feature

In conversation with Bing Yao

By Len Zehr As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to the strategy...

January 7, 2014
Feature

Anavex readies trial of AZ combo drug

By Len Zehr Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical...

December 17, 2013